Shire PLC (LON:SHP)‘s stock had its “buy” rating reaffirmed by research analysts at Berenberg Bank in a research note issued on Wednesday.
Several other equities analysts also recently weighed in on SHP. BNP Paribas reiterated an “outperform” rating and set a GBX 5,900 ($75.43) target price on shares of Shire PLC in a research report on Monday, April 3rd. Barclays PLC reiterated an “overweight” rating and set a GBX 6,500 ($83.10) target price on shares of Shire PLC in a research report on Wednesday, April 12th. Liberum Capital reiterated a “buy” rating and set a GBX 5,500 ($70.31) target price on shares of Shire PLC in a research report on Monday, April 10th. Citigroup Inc reiterated a “buy” rating on shares of Shire PLC in a research report on Wednesday, April 12th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a GBX 6,600 ($84.38) target price on shares of Shire PLC in a research report on Friday, February 17th. One equities research analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of GBX 6,115.60 ($78.18).
Shares of Shire PLC (LON:SHP) opened at 4627.00 on Wednesday. The stock’s market capitalization is GBX 41.77 billion. The company’s 50-day moving average price is GBX 4,694.34 and its 200 day moving average price is GBX 4,701.68. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00.
The business also recently declared a dividend, which will be paid on Tuesday, April 25th. Investors of record on Thursday, March 9th will be given a GBX 20.64 ($0.26) dividend. The ex-dividend date of this dividend is Thursday, March 9th. This represents a yield of 0.43%. This is a positive change from Shire PLC’s previous dividend of $3.51.
In related news, insider William Burns purchased 136 shares of the company’s stock in a transaction that occurred on Friday, March 31st. The stock was bought at an average price of GBX 4,742 ($60.62) per share, for a total transaction of £6,449.12 ($8,244.85).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.